The Download: China’s brain implant ambitions

China has become the first country to approve an invasive brain-computer interface (BCI) for use beyond clinical trials, marking a significant milestone in neurotechnology. The implant, known as NEO, was instrumental in helping Dong Hui, a man paralyzed from the neck down after a car accident, regain limited motor function by enabling him to write his name using brain signals. This approval is expected to accelerate China’s ambitions to lead the global brain implant market and expand applications of BCIs in medical and potentially commercial fields. The NEO implant represents a breakthrough in invasive BCIs, which involve surgically embedding chips directly into the brain to decode neural activity. Unlike non-invasive devices, these implants offer higher precision and responsiveness, making them particularly promising for restoring motor functions in patients with paralysis or neurological disorders. China’s regulatory green light signals growing confidence in the safety and efficacy of such technologies, potentially paving the way for broader adoption and innovation in brain-machine interfaces. China’s progress in this field comes amid intense global competition, with countries like the United States and European nations investing heavily in neurotechnology research. The approval also aligns with China’s broader strategy to dominate emerging technologies, including artificial intelligence and semiconductors. However, the development raises ethical and security questions regarding privacy, data protection, and potential misuse of brain data, which experts say will require careful regulation as the technology matures. This milestone could have far-reaching implications beyond healthcare, potentially enabling new forms of human-computer interaction and augmenting cognitive capabilities. As China pushes forward, the global neurotechnology landscape is likely to evolve rapidly, with increased collaboration and rivalry shaping the future of brain-computer interfaces.